ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Prognostic Significance of the Albumin Platelet Product for Mortality Risk in Pulmonary Embolism: A Retrospective Analysis Based on the MIMIC-IV Database.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundPulmonary embolism (PE) is a leading cause of cardiovascular mortality. The albumin platelet product (APP), a novel biomarker integrating nutritional and inflammatory status, is associated with adverse outcomes in various diseases. However, its prognostic value for mortality in patients with PE remains unclear.MethodsThis retrospective cohort study included 2355 patients with PE from the MIMIC-IV database. The primary exposure was APP, calculated as (albumin [g/dL]×platelet [K/µL]) / 100. The primary endpoints were all-cause mortality at 28 days, 90 days, and 365 days. The association between APP and mortality was assessed using restricted cubic splines (RCS), Kaplan-Meier survival curves, and multivariable Cox proportional hazards models. Subgroup analyses were performed to evaluate consistency across patient characteristics.ResultsUsing the tertile method, participants were stratified into three groups based on their APP levels (Tertile 1, Tertile 2, and Tertile 3), with Tertile1 designated as the reference group for comparative analyses against Tertile 2 and Tertile 3. RCS analysis revealed a statistically significant nonlinear relationship between APP levels and PE mortality (p for nonlinearity < 0.001). Kaplan-Meier survival analysis demonstrated a significantly higher risk of death among patients with lower APP levels (p < 0.01). Multivariable Cox proportional hazards regression models indicated an independent association between low APP levels and increased mortality risk at 28 days, 90 days, and 365 days, both before and after adjustment for potential confounders. Subgroup analyses showed no significant interaction between APP levels and mortality risk in most subgroups examined.ConclusionsIn patients diagnosed with PE, lower APP levels are significantly and independently associated with an increased risk of all-cause mortality. APP serves as a clinically useful predictor of long-term adverse outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.